The Enzygnost® HIV Integral 4 Assay is an HIV combo assay that provides qualitative determination of HIV antibodies, including HIV-1, HIV-1 group O, and HIV-2, plus p24 antigen. Its high specificity and sensitivity enables clinicians to identify HIV infection and initiate treatment up to 14 days earlier than other assays currently on the market.
The HIV Integral 4 Assay meets the specificity and sensitivity requirements of blood banks and other testing facilities. Siemens brings many years of experience, expertise, and leadership in HIV diagnosis to the development of this new HIV combo assay.
The Enzygnost HIV Integral 4 Assay has been validated on the widely used and highly reliable BEP 2000 Advance®*, BEP® III*, and Quadriga BeFree®* Systems.
Download the Enzygnost HIV Integral 4 Assay brochure to learn more about how this new combo assay helps labs move up to the next level of HIV testing performance.